Abstract: The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses. Such compounds are also useful for cleaning purposes. The use of the compounds as surfactants in various types of compositions for treating contact lenses therefore represents a preferred embodiment of the present invention.
Type:
Grant
Filed:
December 10, 2007
Date of Patent:
November 27, 2012
Assignee:
Alcon Research, Ltd.
Inventors:
Howard Allen Ketelson, Nathaniel D. McQueen
Abstract: A process for the syntheses of 17?-hydroxy-7?-methyl-19-nor-17?-pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof.
Type:
Grant
Filed:
March 3, 2004
Date of Patent:
February 8, 2011
Assignee:
Resolution Chemicals Limited
Inventors:
Alan K. Greenwood, Derek McHattie, Parveen Bhatarah
Abstract: Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.
Type:
Grant
Filed:
November 8, 2005
Date of Patent:
February 1, 2011
Assignee:
Alcon, Inc.
Inventors:
Peter G. Klimko, Mark R. Hellberg, David P. Bingaman, Daniel A. Gamache
Abstract: A method is disclosed herein comprising administering a compound and a second drug to an eye of a mammal for the treatment of glaucoma or the reduction of intraocular pressure, said compound represented by the general formula I; wherein A, B, D, X, Y, Z, R1, R3 and R4 are as defined in the specification.
Type:
Grant
Filed:
May 16, 2005
Date of Patent:
January 18, 2011
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Scott M. Whitcup, Wha-Bin Im
Abstract: A process for preparing 17?-substituted 4-azaandrost-1-en-3-one compounds of the general formula (I): or a pharmaceutically approved salt thereof, where R is hydroxyl, optionally substituted, linear or branched (C1-C2)alkyl or (C1-C12)alkenyl; phenyl or benzyl; an —OR1 radical, or an —NHR1 radical, or an —NR1R2 radical; R1 is hydrogen, optionally substituted, linear or branched (C1-C12)alkyl or (C1-C12)alkenyl, or optionally substituted phenyl; R2 is hydrogen, methyl, ethyl or propyl; or —NR1R2 is a 5- or 6-membered heterocyclic ring, by (A) introducing protecting groups into the 3-keto-4-aza moiety of the corresponding 1,2-dihydro compound, so that a compound of the general formula (III) is formed: where R3 is trialkylsilyl or, together with R4, the —C(O)—C(O)— or —C(O)—Y—C(O)— radical; R4 is alkyloxycarbonyl or phenyloxycarbonyl, preferably Boc (=tert-butyloxycarbonyl); or trialkylsilyl, or, together with R3, the —C(O)—C(O)— or —C(O)—Y—C(O)— radical; Y is —[C(R5)(R6)]n— or —CH(R5)?CH(R6)—, or ort
Type:
Grant
Filed:
July 2, 2003
Date of Patent:
January 18, 2011
Assignee:
Siegfried Ltd.
Inventors:
Norber Schärer, Beat Webber, Beat W Müller
Abstract: Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
Type:
Grant
Filed:
December 19, 2007
Date of Patent:
October 26, 2010
Assignee:
Alcon Research, Ltd.
Inventors:
Hwang-Hsing Chen, Andrew Rusinko, Mark R. Hellberg, Bryon S. Severns, Alan J. Henderson, Cheng Guo, Mark Hadden